Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs.
Radiat Res
; 198(3): 306-317, 2022 09 01.
Article
in English
| MEDLINE | ID: covidwho-2079878
ABSTRACT
COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Radiation Injuries
/
COVID-19
Type of study:
Etiology study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Radiat Res
Year:
2022
Document Type:
Article
Affiliation country:
RADE-22-00058.1
Similar
MEDLINE
...
LILACS
LIS